Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition ...

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary ...

The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

SpringWorks Therapeutics has established itself as a promising player in the U.S. Small & Mid Cap Biotechnology sector. The company’s primary focus has been on developing innovative therapies ...

Merck KGaA, Darmstadt, Germany has closed the acquisition of SpringWorks Therapeutics Inc. for an enterprise value of $3.4 billion.

EMA advisor endorses treatments from Madrigal, Ipsen, and SpringWorks for various conditions. Read more here.

SpringWorks Therapeutics announced that the European Medicine Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nirogacestat, an oral gamma secretase ...

SpringWorks Therapeutics Inc. (NASDAQ:SWTX) is one of the best biotech stocks to invest in now. On June 20, SpringWorks Therapeutics announced that the European Medicine Agency’s Committee for ...

The new biotech SpringWorks has spun out of Pfizer on a mission to develop four badly-needed drugs for rare and serious diseases.

About SpringWorks Therapeutics SpringWorks is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with severe rare diseases and cancer.

The Fiera Capital SMID Cap Growth SMA returned -10.7% (net of fees), and slightly outperformed its benchmark for Q1 2025.